Nanoform Finland Oyj Stock Nasdaq Helsinki
Equities
FI4000330972
Biotechnology & Medical Research
Sales 2024 * | 7.48M 7.97M | Sales 2025 * | 14.6M 15.55M | Capitalization | 199M 212M |
---|---|---|---|---|---|
Net income 2024 * | -15M -15.98M | Net income 2025 * | -11M -11.72M | EV / Sales 2024 * | 22.5 x |
Net cash position 2024 * | 31M 33.03M | Net cash position 2025 * | 21.34M 22.73M | EV / Sales 2025 * | 12.2 x |
P/E ratio 2024 * |
-13
x | P/E ratio 2025 * |
-18.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.1% |
Latest transcript on Nanoform Finland Oyj
Managers | Title | Age | Since |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 14-12-31 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 14-12-31 |
Investor Relations Contact | - | 19-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-04-01 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 18-12-31 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 14-12-31 |
1st Jan change | Capi. | |
---|---|---|
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |